- Home
- PLRX vs ORIC Comparison
PLRX vs ORIC Comparison
Compare PLRX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | ORIC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 1.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLRX | ORIC |
|---|---|---|
| Price | $1.35 | $11.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $2.50 | ★ $20.00 |
| AVG Volume (30 Days) | 601.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | 19.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $3.90 |
| 52 Week High | $1.95 | $14.93 |
Technical Indicators
Market Signals| Indicator | PLRX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 47.21 |
| Support Level | $1.12 | $11.74 |
| Resistance Level | $1.36 | $12.89 |
| Average True Range (ATR) | 0.06 | 0.99 |
| MACD | 0.01 | -0.21 |
| Stochastic Oscillator | 58.14 | 24.46 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.